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Abstract
The crumbs protein homolog 3 (CRB3) regulates the tight junction to help maintain (P = 0.048). Indeed, levels of CRB3 mRNA were higher in non-TNBC than TNBC in both Metabric (P = 3.682e-10) and TCGA datasets (P = 2.501e-07). The in vitro data showed that CRB3 expression was higher in luminal (MCF7 and T47D) than in HER2 (MDA-MB-453 and SK-BR-3) and basal (MDA-MB-231 and BT-549) breast cancer cell lines. More interestingly, ERα regulated expression of CRB3 protein in MCF7 and BT-549 cells and ERα expression was associated with CRB3 expression in breast cancer tissues specimens. This study demonstrated that ERα could be a novel regulator for CRB3 expression in breast cancer.
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| INTRODUC TI ON
Breast cancer is the most frequently diagnosed malignancy in women worldwide with an estimated 1.7 million new cases and more than a half of million deaths occurring in 2012. Breast cancer originates from mammary epithelial cells and the common feature of the epithelium is cell polarity, which includes the shape, structure, and function through the tight junctions, desmosomes, and adherens junctions. 8, 9 Thus, establishment and maintenance of the epithelial polarity relies on three cell polarity complexes, ie, the partitioning defective (PAR) complex, the Scribble (SCRIB) complex, and the Crumbs (CRB) complex. 10 Indeed, previous studies demonstrated that apical polarity protein CRB3, a crumbs isoform, maintains epithelial polarity through tight junctions.
11-13
For example, CRB3 knockout mice revealed that CRB3 was crucial for epithelial morphogenesis and that mice would die shortly after birth with cystic kidneys and proteinaceous debris throughout the lungs, 14 and the CRB3 knockout mice had improper clearance of the airway, cystic kidney, and villus fusion of the intestinal epithelium. 15 Other recent studies showed that CRB3 could also act as a tumour suppressor in epithelial cells, eg, knockout of CRB3 promoted tumourigenesis potential of cultured epithelial cells and tumour cell metastasis in nude mice. 16, 17 Moreover, reduced CRB3 expression induced an increase in the level of cytoplasmic β-catenin in intestinal epithelial cells and β-catenin was accumulated in most cases of colon cancers, 15 while disruption of CRB complex predisposed TGF-β-mediated epithelial-to-mesenchymal transitions (EMT). 18 However, restoration of CRB3 expression re-established cell-cell junctions, cell polarity, and contact growth inhibition, but inhibited tumour cell migration and metastasis. 17 Recently, comparison of transcriptomic and comparative genomic hybridization analysis (CGH) data revealed that CRB3 is localized at chromosome 19 and CRB3 expression was upregulated in male lactotroph tumours, 19 indicating that aberrant CRB3 expression could associate with tumorigenesis.
In this study, we analyzed expression of CRB3 protein in breast cancer tissues to associate with tumour cell phenotypes and therefore, to identify the role of CRB3 in development and progression of breast cancer.
| RE SULTS

| Association of CRB3 protein expression with TNBC
Our previous study revealed that CRB3 expression was lower in breast cancer compared with that of normal mammary gland tissues. 20 In this study, we detected CRB3 expression in 192 invasive human breast cancers ( 
| Association of CRB3 mRNA level with TNBC using Molecular Taxonomy of Breast Cancer International Consortium (Metabric) and TCGA datasets
To validate our data on the association of CRB3 expression with TNBC, we downloaded these two datasets and analyzed accordingly. We found that levels of CRB3 mRNA were higher in ER+ than ER− breast cancer in both Metabric (P = 2.145932e-09) and TCGA datasets (P = 2.919621e-08; Figure 2A ) and was higher in PR+ than PR− breast cancer in Metabric (P = 4.41747e-08) and TCGA datasets (P = 8.92533e-05; Figure 2B ). Overall, levels of CRB3 mRNA were higher in non-TNBC than TNBC in both Metabric (P = 3.682213e-10)
and TCGA datasets (P = 2.500548e-07; Figure 2C ). These data further supported our own analysis of CRB3 protein (Table 1 ).
| Association of CRB3 expression with TNBC phenotype in breast cancer cell lines
To confirm our ex vivo data, we assessed CRB3 expression in different breast cancer cell lines and found that CRB3 expression was higher in luminal (MCF7 and T47D) than in HER2 (MDA-MB-453 and SK-BR-3) and basal (MDA-MB-231 and BT-549) breast cancer cell lines (P = 0.0001; Figure 3A ,B).
| ERα upregulation of CRB3 protein levels in MCF7 and BT-549 cells
Thus far, our current study demonstrated that CRB3 expression was associated with TNBC phenotypes ex vivo and in vitro. We speculated that ERα could be a novel regulator of CRB3 since ERα is a nuclear transcription factor, 21 and consideration of ER could also regulate PR expression. [22] [23] [24] [25] [26] Our data showed that knockdown of ERα expression in luminal cell MCF7 breast cancer cells significantly downregulated levels of CRB3 mRNA and protein ( Figure 4A ,B). Additionally, CRB3 protein was significantly reduced in MCF7 cells after knockdown of ERα expression in the GEO database ( Figure 4C ; P < 0.0001, GSE27473). CRB3 expression was higher in ER+ breast cancer ZR-75-1 cells than in ER− breast cancer MDA-MB-231 cells isolated from the mouse bone marrow ( Figure 4D ; P = 0.0006, GSE27515). Furthermore, there was an association of ERα and CRB3 expression in the ex vivo GEPIA dataset (gepia.cancer-pku.cn/index.html; P = 3.6e-15, R = 0.24; Figure 4E ). In addition, we detected CRB3 expression after ERα was overexpressed in TNBC cell line BT-549 and found that levels of CRB3 protein increased after ERα overexpression, while CRB3 mRNA levels were not significantly altered ( Figure 4F ). Therefore, we speculated that ERα indirectly regulates CRB3 by stabilization of CRB3 protein ( Figure 4G ). Our findings indicate that ERα could be a novel regulator for CRB3 expression in breast cancer. 34, 35 In our current study, we sought to identify novel targets for the future control of TNBC and found that CRB3 expression was significantly lost in TNBC tissues and cell lines, but the molecular events responsible for loss of CRB3 expression in human breast tumours remain to be determined. Our previous study revealed that CRB3 expression was lower in breast Moreover, ERα expression was inversely associated with tumour cell EMT and cancer stem-like cell phenotypes. 43, 44 In the current study, we found that CRB3 expression was inversely associated with tumour size (Table 1) , which is consistent with previous studies showing that downregulation of CRB3 expression induced breast cancer cell proliferation, whereas CRB3 overexpression inhibited proliferation of human breast cell lines. 20, 45, 46 Our previous study also showed that the downregulation of CRB3 expression increased migration and invasion of breast cancer cells, whereas CRB3 overexpression inhibited migration and invasion of human breast and kidney cancer cell lines. 20, 47 Our previous study also showed that CRB3 expression was an independent favourable predictor for renal clear cell carcinoma.
| D ISCUSS I ON
TA B LE 1 Association of CRB3 expression with clinicopathological data from breast cancer patients (n = 192)
47
In summary, our current study is a proof-of-principle. The data from our current study demonstrated that expression of CRB3 
| MATERIAL S AND ME THODS
| Immunohistochemical analysis (IHC)
This study was approved by the ethics committee of human subject GCA CTG-3′ and 5′-GAA GAC CAC GAT GAT AGC AGT GA-3′; β-actin, 5′-CAT GTA CGT TGC TAT CCA GGC-3′ and 5′-CTC CTT AAT GTC ACG CAC GAT-3′. The experiment was performed in triplicate and level of CRB mRNA was normalized to β-actin using the 2 −(Ct-Ct) method.
| Western blot
Whole-cell lysates were prepared using a modified RIPA buffer and protein samples were separated in sodium dodecyl sulfate-polyacrylamide gel electrophoresis SDS-PAGE) gels and transferred onto PVDF membranes (Millipore). We then followed a standard
Western blotting protocol to blot these membranes using an anti- 
| Statistical analysis
Statistical analyses were performed using GraphPad Prism Version 7.0 (GraphPad Software). The correlation between CRB3 expression and clinicopathological characteristics was assessed by using
Fisher's exact test or the chi-square test, while in vitro data between two groups were assessed by using unpaired t tests and Pearson correlation coefficient tests, while the data on three groups were compared using one-way analysis of variance (ANOVA) followed by using Dunnett's multiple comparisons test. All statistical tests were two-sided and all results were expressed as the mean ± SEM for *P < 0.05 or **P < 0.01 All in vitro data were obtained from at least three experimental replicates with similar results. 
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